JP2021527090A - 老化関連神経変性の進行および/または発症を治療および/または予防するための方法および組成物 - Google Patents
老化関連神経変性の進行および/または発症を治療および/または予防するための方法および組成物 Download PDFInfo
- Publication number
- JP2021527090A JP2021527090A JP2020569002A JP2020569002A JP2021527090A JP 2021527090 A JP2021527090 A JP 2021527090A JP 2020569002 A JP2020569002 A JP 2020569002A JP 2020569002 A JP2020569002 A JP 2020569002A JP 2021527090 A JP2021527090 A JP 2021527090A
- Authority
- JP
- Japan
- Prior art keywords
- aminosterol
- dose
- subject
- derivative
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(C)[C@](*)CC[C@@](C)C(CC1)[C@@](C)(CCC2[C@@](C)(CC[C@@](C3)NCCCN(C)CC[C@@](C)C=NCCCN*)[C@]3C3)C1C2[C@@]3O Chemical compound CC(C)[C@](*)CC[C@@](C)C(CC1)[C@@](C)(CCC2[C@@](C)(CC[C@@](C3)NCCCN(C)CC[C@@](C)C=NCCCN*)[C@]3C3)C1C2[C@@]3O 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862684496P | 2018-06-13 | 2018-06-13 | |
| US62/684,496 | 2018-06-13 | ||
| PCT/US2019/036946 WO2019241503A1 (en) | 2018-06-13 | 2019-06-13 | Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021527090A true JP2021527090A (ja) | 2021-10-11 |
| JP2021527090A5 JP2021527090A5 (cg-RX-API-DMAC7.html) | 2022-04-22 |
Family
ID=68838925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020569002A Pending JP2021527090A (ja) | 2018-06-13 | 2019-06-13 | 老化関連神経変性の進行および/または発症を治療および/または予防するための方法および組成物 |
Country Status (11)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020028791A1 (en) * | 2018-08-03 | 2020-02-06 | Enterin Laboratories | Low dosage intranasal aminosterol dosage forms and methods of using the same |
| US11464789B2 (en) | 2018-08-03 | 2022-10-11 | Enterin, Inc. | Aminosterol compositions and methods of using the same for treating schizophrenia |
| WO2020028810A1 (en) * | 2018-08-03 | 2020-02-06 | Enterin Laboratories | Compositions and methods for treating brain-gut disorders |
| CN110827282B (zh) * | 2020-01-13 | 2020-04-10 | 南京慧脑云计算有限公司 | 一种基于磁共振成像的脑白质纤维束示踪分析方法及系统 |
| CN111110873A (zh) * | 2020-02-24 | 2020-05-08 | 苏州欣影生物医药技术有限公司 | 一种磁共振/核医学双模态分子影像探针的制备方法 |
| CN111528839B (zh) | 2020-05-29 | 2023-06-23 | 北京京东方健康科技有限公司 | 睡眠检测方法和装置、助眠设备和方法 |
| AU2021446815B2 (en) * | 2021-05-21 | 2025-09-11 | Animuscure Inc. | Composition comprising inotodiol for prevention or treatment of muscular disease |
| WO2025054408A1 (en) * | 2023-09-07 | 2025-03-13 | NeuroTherapia, Inc. | Methods of treating cognitive impairment |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010538072A (ja) * | 2007-09-06 | 2010-12-09 | ジェナエラ コーポレイション | 糖尿病を治療する方法 |
| JP2017519775A (ja) * | 2014-06-23 | 2017-07-20 | ザスロフ,マイケル | 腸の腸内分泌系を関連疾患又は病状の処置のために刺激する方法及び組成物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143738A (en) * | 1995-06-07 | 2000-11-07 | Magainin Pharmaceuticals, Inc. | Therapeutic uses for an aminosterol compound |
| WO2011066260A2 (en) * | 2009-11-25 | 2011-06-03 | Michael Zasloff | Formulations comprising aminosterols |
-
2019
- 2019-06-13 JP JP2020569002A patent/JP2021527090A/ja active Pending
- 2019-06-13 SG SG11202012343TA patent/SG11202012343TA/en unknown
- 2019-06-13 EP EP19818961.5A patent/EP3806862A4/en not_active Withdrawn
- 2019-06-13 WO PCT/US2019/036946 patent/WO2019241503A1/en not_active Ceased
- 2019-06-13 KR KR1020217000559A patent/KR20210009422A/ko not_active Ceased
- 2019-06-13 US US16/440,414 patent/US20190381071A1/en not_active Abandoned
- 2019-06-13 MX MX2020013614A patent/MX2020013614A/es unknown
- 2019-06-13 BR BR112020025296-4A patent/BR112020025296A2/pt not_active IP Right Cessation
- 2019-06-13 CA CA3103463A patent/CA3103463A1/en active Pending
- 2019-06-13 AU AU2019285065A patent/AU2019285065A1/en not_active Abandoned
- 2019-06-13 US US17/251,322 patent/US20210252023A1/en not_active Abandoned
- 2019-06-13 CN CN201980052151.2A patent/CN112566641A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010538072A (ja) * | 2007-09-06 | 2010-12-09 | ジェナエラ コーポレイション | 糖尿病を治療する方法 |
| JP2017519775A (ja) * | 2014-06-23 | 2017-07-20 | ザスロフ,マイケル | 腸の腸内分泌系を関連疾患又は病状の処置のために刺激する方法及び組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020025296A2 (pt) | 2021-03-09 |
| SG11202012343TA (en) | 2021-01-28 |
| CA3103463A1 (en) | 2019-12-19 |
| KR20210009422A (ko) | 2021-01-26 |
| EP3806862A4 (en) | 2022-07-06 |
| WO2019241503A1 (en) | 2019-12-19 |
| EP3806862A1 (en) | 2021-04-21 |
| US20190381071A1 (en) | 2019-12-19 |
| US20210252023A1 (en) | 2021-08-19 |
| CN112566641A (zh) | 2021-03-26 |
| MX2020013614A (es) | 2021-05-27 |
| AU2019285065A1 (en) | 2021-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7312169B2 (ja) | 遺伝性てんかん性障害の処置に使用するガナキソロン | |
| US20210252023A1 (en) | Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration | |
| JP6957602B2 (ja) | 神経変性疾患のための治療薬 | |
| JP7352542B2 (ja) | 運動失調を処置するためのリルゾールプロドラッグの使用 | |
| KR102549684B1 (ko) | 신경퇴행성 질병에 대한 치료제 | |
| JP2021527090A5 (cg-RX-API-DMAC7.html) | ||
| KR20190039226A (ko) | 리소좀 축적 질환과 관련된 약제 조성물 및 용도 | |
| AU2017277005A1 (en) | Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement | |
| KR20200146038A (ko) | 환각 및 이와 관련된 상태를 치료하는 방법 및 조성물 | |
| US20200129528A1 (en) | Methods for treating blood pressure conditions using aminosterol compositions | |
| EP3829537A1 (en) | Low dosage intranasal aminosterol dosage forms and methods of using the same | |
| US20200038420A1 (en) | Aminosterol compositions and methods of using the same for treating depression | |
| US20190247405A1 (en) | Treatment of sma | |
| TW202539621A (zh) | 用於治療巴金森氏症的治療劑 | |
| Dahimene et al. | Genotype-phenotype correlations in a French cohort with Becker muscular dystrophy: focus on cognitive aspects | |
| HK40037184A (en) | Use of riluzole prodrugs to treat ataxias | |
| BR112020007657B1 (pt) | Uso de leucina, acetil-leucina ou um sal farmaceuticamente aceitável da mesma para tratamento da síndrome das pernas inquietas (rls) | |
| JPWO2014088106A1 (ja) | 線維筋痛症の予防または治療薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220414 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220414 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230221 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230224 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230919 |